Abstract 【Objective】To study the correlation between circulating miR-221 level and the prognosis of ovarian cancer patients. 【Methods】A total of 84 ovarian cancer patients admitted to the Department of Obstetrics and Gynecology of Xi'an XD Group Hospital from January 2015 to January 2020 were selected as the research objects. At the same time, 84 healthy volunteers in the same period in our hospital were selected as the control group. The relative expression of miR-221 in the patient's serum was determined, and the relationship of the circulating miR-221 level with the patient's disease stage, lymph node metastasis, pathological differentiation, histopathological type and prognosis were analyzed. 【Results】The relative expression of miR-221 in the serum of the ovarian cancer group was(7.152±2.61), which was higher than that of the control group(2.102±0.49); and the difference was statistically significant(t=17.429, P<0.05). The level of circulating miR-221 was significantly related to the stage of ovarian cancer(P=0.043), lymph node metastasis(P=0.014), and pathological differentiation type(P<0.001). By the end of the follow-up, a total of 32(38.1%) of 84 patients died, 9(10.7%) were lost to follow-up, 43(51.2%) were alive, and the median follow-up time was 30(4～51) months. The circulating miR-221 level was significantly correlated with overall survival(OS)(P<0.001), and the correlation coefficient was -0.775. The median survival time of patients in the low-level group was 42 months(40.2±4.6), and the median survival time of patients in the high-level group was 29 months(29.3±3.6). The OS of the low-level group was significantly better than that of the high-level group(P<0.001). 【Conclusion】The late disease stage, lymph node metastasis, and poor pathological differentiation of ovarian cancer patients are associated with higher circulating Mir-221 levels. The level of circulating miR-221 is significantly related to OS, and patients with lower levels of circulating miR-221 have a better prognosis.
YUE Hua,WANG Zhen. Serum Expression Level and Clinical Significance of MiR-221 in Patients with Ovarian Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(7): 1028-1030.
[1] GUO L Y, WU A H, WANG Y X, et al. Deep learning-based ovarian cancer subtypes identification using multi-omics data[J].Biol Data Min,2020,13:10. [2] TORRE L A, TRABERT B, DESANTIS C E, et al. Ovarian cancer statistics, 2018[J].CA Cancer J Clin,2018,68(4):284-296. [3] KARGO A S, COULTER A, JENSEN P T,et al. Proactive use of PROMs in ovarian cancer survivors:a systematic review[J].J Ovarian Res,2019,12(1):63. [4] GUPTA K K, GUPTA V K, NAUMANN R W. Ovarian cancer:screening and future directions[J].Int J Gynecol Cancer,2019,29(1):195-200. [5] WU X, ZENG R, WU S, et al. Comprehensive expression analysis of miRNA in breast cancer at the miRNA and isomiR levels[J].Gene,2015,557(2):195-200. [6] XIE X, HUANG Y, CHEN L, et al.miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF[J].Oncol Lett,2018,16(5):6697-6704. [7] 李晶,吴妙芳,林仲秋.《FIGO 2018妇癌报告》——卵巢癌、输卵管癌、腹膜癌诊治指南解读[J].中国实用妇科与产科杂志,2019,35(3):304-314. [8] JIN J. Screening for ovarian cancer[J].JAMA,2018,319(6):624. [9] CHIEN J, POOLE E M. Ovarian Cancer prevention, screening, and early detection:report from the 11th biennial ovarian cancer research symposium[J].Int J Gynecol Cancer,2017,27(Suppl 5):S20-S22. [10] COUKOS G, TANYI J, KANDALAFT L E. Opportunities in immunotherapy of ovarian cancer[J].Ann Oncol,2016,27(Suppl 1):i11-i15. [11] LI J, LI Q, HUANG H, et al. Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer[J].Int J Oncol,2017,50(4):1087-1096. [12] HONG F, LI Y, XU Y, ZHU L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer[J].J Int Med Res,2013,41(1):64-71. [13] 刘培红,汤菲,刘咏. 卵巢上皮癌患者血清中miR-221的表达及其诊断价值[J].国际检验医学杂志,2019,40(20):2471-2474.
2021, Vol. 38 
